Affini-T is developing specific TCR-based immunotherapies to treat solid tumors with autologous T Cell therapies and bispecific T Cell engager therapies
Bispecific T Cell Engagers
Affini-T's unique cellular therapies begin with patient-collected T cells engineered to express a TCR targeting oncogenic driver mutations.
Affini-T also engineers these cells with features designed to enhance their persistence, survival and expansion in the patient.
Autologous TCR-T Cell Therapy
Targeting Oncogene Mutations in TumorsOnce administered to the patient the engineered T Cells specifically seek out and destroy tumor cells that display the mutant peptide, while sparing healthy cells.
Autologous TCR-T Cell Therapy
Generation of bispecific T Cell Engagers. Off-the-shelf bispecific infusion to eligible cancer patients
